Laureate Education Reports Financial Results for the First Quarter of 2024 Company Increases Full-Year 2024 Guidance MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the first quarter of 2024. First Quarter 2024 Highlights (compared to first quarter 2023): New enrollments increased 1%.Total enrollments increased 5%.On a reported basis, revenue increased 10% to $275.4 million. On an organic constant currency basis1, revenue increased 1%...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into ...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. dollars. Total net revenue was $50.3 million for the three months ended March 31, 2024 and $34.4 million for the same period in 2023. representing growth of approximately 46%. Net product revenue was $48.1 million for the three months ended March 31, 2024 and $34.3 million for the same period in 2023, representing growth of approximately 40%. Aurinia rapidly com...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists. Aurinia is on a mission to tackle the toughest challenges that the LN community faces through collaborative efforts with key stakeholders across the healthcare ecosystem, including patien...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyond one year. The label now includes three-year data from the AURORA 2 double-blind, placebo-controlled extension study, which assessed the long-term safety and tolerability of LUPKYNIS in combination with mycophenolate mofetil (MMF) and low-dose glucocorticoids, compared with MM...
DXL Big + Tall Announces Strategic Collaboration with Nordstrom to Bring Fit Expertise to More Big + Tall Customers CANTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (Nasdaq: DXLG), the country's leading retailer specializing in Big + Tall men's clothing and shoes, is excited to announce a strategic collaboration with Nordstrom, Inc., a leading fashion retailer, which will launch on their digital platform. This collaboration marks a significant step in extending DXL’s “fit” expertise and diverse style selection to a new segment of the underserved Big + Tall cons...
SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- onsemi (the “Company”) (Nasdaq: ON) today announced results for the first quarter of 2024 with the following highlights: Revenue of $1,862.7 million GAAP gross margin and non-GAAP gross margin of 45.8% and 45.9%, respectively GAAP operating margin and non-GAAP operating margin of 28.2% and 29.0%, respectively GAAP diluted earnings per share and non-GAAP diluted earnings per share of $1.04 and $1.08, respectively Returned ~100% of free cash flow over last twelve months to shareholders through stock repurchases “The structural changes we hav...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Upgrading Europe to Overweight Considering the fact that several 5% pullbacks and roughly one 10% pullback are to be expected in any given year, we continue to view the latest pullback as healthy and normal within the ongoing bull market -- MSCI ACWI (ACWI-US) has had a 5.5% pullback from its 2024 highs, while the EURO STOXX 50 pulled back 4.5%. We discussed last Thursday (4/18/24 Int'l Compass) how further downside may be limited with these two indexes already 4-5% off their highs, combined wi...
A director at Biohaven Ltd bought 25,503 shares at 39.179USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET. To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.